

Special Issue

Emerging Drug Discovery Approaches against Neglected Diseases

Message from the Guest Editor

Scientists are cordially invited to contribute original research papers or reviews to this Special Issue of *Molecules*, which reports on the design, synthesis, and evaluation of potentially-active compounds in the different subjects of medicinal chemistry and pharmacology. In addition, old or new drugs can also be evaluated for this Special Issue entitled “Emerging Drug Discovery Approaches against Neglected Diseases”. A variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven research and development. In this Special Issue, focus is on the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), leishmaniasis, Chagas disease, pediatric HIV, filarial diseases, mycetoma, hepatitis C, and even malaria.

Guest Editor

Dr. Nuno Vale

Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

Deadline for manuscript submissions

closed (31 July 2020)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/30215

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).